Journal for ImmunoTherapy of Cancer
Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC)
Basic Tumor Immunology
Section edited by Cornelis J.M. Melief, MD, PhD
Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses.
- RESEARCH ARTICLE
A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
Clinical success with chimeric antigen receptor (CAR)- based immunotherapy for leukemia has been accompanied by the associated finding that antigen-escape variants of the disease are responsible for relapse. T...Journal for ImmunoTherapy of Cancer 2017 5:42Published on: 16 May 2017 - RESEARCH ARTICLE
Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation
Human γδ T cells expressing Vγ2Vδ2 T cell receptors monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy with...Journal for ImmunoTherapy of Cancer 2017 5:9Published on: 21 February 2017 - RESEARCH ARTICLE
Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model
Although therapeutic cancer vaccines have been mostly disappointing in the clinic, the advent of novel immunotherapies and the future promise of neoantigen-based therapies have created the need for new vaccine...Journal for ImmunoTherapy of Cancer 2016 4:96Published on: 20 December 2016 - RESEARCH ARTICLE
Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases
Tumors avoid destruction by cytotoxic T cells (CTL) and natural killer (NK) cells by downregulation of classical human leukocyte antigens (HLA) and overexpression of non-classical HLA. This is the first study ...Journal for ImmunoTherapy of Cancer 2016 4:78Published on: 15 November 2016 - RESEARCH ARTICLE
Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide
Future cancer immunotherapies will combine multiple treatments to generate functional immune responses to cancer antigens through synergistic, multi-modal mechanisms. In this study we explored the combination ...Journal for ImmunoTherapy of Cancer 2016 4:68Published on: 18 October 2016 - RESEARCH ARTICLE
Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages – a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape
Ovarian cancer (OvCA) tissues show abundant expression of the ectonucleotidases CD39 and CD73 which generate immunomodulatory adenosine, thereby inhibiting cytotoxic lymphocytes. Little, however, is known abou...Journal for ImmunoTherapy of Cancer 2016 4:49Published on: 16 August 2016 - RESEARCH ARTICLE
Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5
Therapeutic resistance and tumor recurrence are two major hurdles in the treatment of pancreatic ductal adenocarcinoma. Recent findings suggest that both of these attributes are associated with a small subset ...Journal for ImmunoTherapy of Cancer 2016 4:33Published on: 21 June 2016 - RESEARCH ARTICLE
Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient
Adoptive T-cell based immunotherapies constitute a promising approach to treat cancer, however, a major problem is to obtain effective and long-lasting anti-tumor responses. Lack of response may be due to insu...Journal for ImmunoTherapy of Cancer 2016 4:21Published on: 19 April 2016 - RESEARCH ARTICLE
Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant
Annexin A2 (ANXA2) is a pleiotropic, calcium-dependent, phospholipid-binding protein with a broad tissue distribution. It can be intracellular, membrane-bound, or secreted, and it exists as a monomer or hetero...Journal for ImmunoTherapy of Cancer 2016 4:11Published on: 16 February 2016 - RESEARCH ARTICLE
Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma
A current focus in cancer treatment is to broaden responses to immunotherapy. One reason these therapies may prove inadequate is that T lymphocytes fail to recognize the tumor due to differences in immunogenic...Journal for ImmunoTherapy of Cancer 2016 4:10Published on: 16 February 2016 - RESEARCH ARTICLE
Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning
Lymphodepletion enhances adoptive T cell transfer (ACT) therapy by activating the innate immune system via microbes released from the radiation-injured gut. Microbial components, such as LPS, are key mediators...Journal for ImmunoTherapy of Cancer 2016 4:6Published on: 16 February 2016 - RESEARCH ARTICLE
Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors
Adoptive cell transfer of tumor-specific T lymphocytes (T cells) is proving to be an effective strategy for treating established tumors in cancer patients. One method of generating these cells is accomplished ...Journal for ImmunoTherapy of Cancer 2015 3:55Published on: 15 December 2015 - RESEARCH ARTICLE
Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment
Tasquinimod (a quinoline-3-carboxyamide) is a small molecule immunotherapy with demonstrated effects on the tumor microenvironment (TME) involving immunomodulation, anti-angiogenesis and inhibition of metastas...Journal for ImmunoTherapy of Cancer 2015 3:53Published on: 15 December 2015 - RESEARCH ARTICLE
Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
Clinical targeting of TNFR family of receptors (CD40, CD134 and CD137) with immunostimulatory monoclonal antibodies has been successful in cancer immunotherapy. However, targeting of CD27 with a mAb is a relat...Journal for ImmunoTherapy of Cancer 2015 3:37Published on: 18 August 2015 - RESEARCH ARTICLE
Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer
Ovarian cancer is immunogenic and residual tumor volume after surgery is known to be prognostic. Ovarian cancer often follows a recurring-remitting course and microscopic disease states may present ideal oppor...Journal for ImmunoTherapy of Cancer 2015 3:16Published on: 19 May 2015 - RESEARCH ARTICLE
NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade
Melanoma is one of the few types of cancer with an increasing annual incidence. While a number of immunotherapies for melanoma have been associated with significant clinical benefit, including high-dose IL-2 a...Journal for ImmunoTherapy of Cancer 2015 3:18Published on: 19 May 2015 - RESEARCH ARTICLE
Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model
The complex interactions that occur between human tumors, tumor infiltrating lymphocytes (TIL) and the systemic immune system are likely to define critical factors in the host response to cancer. While convent...Journal for ImmunoTherapy of Cancer 2015 3:12Published on: 21 April 2015 - RESEARCH ARTICLE
T cell-NF-κB activation is required for tumor control in vivo
T cells have the capacity to eliminate tumors but the signaling pathways by which they do so are incompletely understood. T cell priming requires activation of the transcription factors AP-1, NFAT and NF-κB do...Journal for ImmunoTherapy of Cancer 2015 3:1Published on: 20 January 2015 - RESEARCH ARTICLE
Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma
Multiple myeloma is characterized by the presence of transformed neoplastic plasma cells in the bone marrow and is generally considered to be an incurable disease. Successful treatments will likely require mul...Journal for ImmunoTherapy of Cancer 2015 3:2Published on: 20 January 2015 - RESEARCH ARTICLE
iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine
Therapeutic cancer vaccines aim to boost the natural immunity against transformed cancer cells, and a series of adjuvants and co-stimulatory molecules have been proposed to enhance the immune response against ...Journal for ImmunoTherapy of Cancer 2014 2:39Published on: 18 November 2014
.png)
No hay comentarios:
Publicar un comentario